MEGAN HUDSON: Open Payments
NPI 1104560796 · MARTINSVILLE, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$730 in 48 payments from 16 companies in 2025. Trend: 2023 $899 · 2024 $1,029 · 2025 $730
Food & beverage: $730
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 19 | $199 |
| Otsuka America Pharmaceutical, Inc. | 4 | $74 |
| AstraZeneca Pharmaceuticals LP | 4 | $63 |
| Novartis Pharmaceuticals Corporation | 3 | $55 |
| PFIZER INC. | 3 | $50 |
| Amgen Inc. | 2 | $38 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $37 |
| Lilly USA, LLC | 2 | $35 |
| Esperion Therapeutics, Inc. | 2 | $32 |
| Vanda Pharmaceuticals Inc. | 1 | $28 |
Products named: VRAYLAR, QULIPTA, REXULTI, LEQVIO, FARXIGA, REPATHA, XIFAXAN, NURTEC ODT.
Industry payments across VA — which companies pay providers there.
